Unlocking Hope for Cancer Patients Using PDT
CLINICAL INFLEXION POINT
PDT FOR TREATMENT OF CANCERS AND INFECTIOUS DISEASES
3
Clinical stage life-science company using proprietary Photodynamic Therapy (PDT) technology
(PhotosoftTM) to treat a range of cancers and infectious diseases.
Focus on unmet medical needs particularly in Asian-centric indications that are globally relevant
Existing (Peter Mac, Hudson Institute) and future international partnership potential
CANCER (INV043)
Multiple cancer indications
■ Ablation and activation of immune response
Improved efficacy of immune checkpoint
inhibitor (ICI) treatments when in combination
Topical and systemic formulations
Strong therapeutic profile
Target Indications
■ Non-melanoma skin cancer (topical)
■ Solid tumour cancer TBD (IV)
■
Anogenital cancer (topical)
■ Additional TBD
INFECTIOUS DISEASES
■ Broad spectrum antimicrobial activity
■ No known drug resistance (to address AMR)
Commercially viable focus
■
Target Indications
■ Oral antimicrobial: Peri-implant mucositis
Human Papilloma Virus (HPV), with Dr.inB
■ Additional TBD
Core Australian cancer development fully funded
by RMW Cho Group, inventor/owner of Photosoft¹
Expanded Territories in cancer and AID (incl. in
Asia Pacific¹, and US/Canada for ID). Invion
co-contributes 25% pre-clinical & 75% clinical costs
1 Includes Asia and Oceania (other than Australia and New Zealand, which are covered under a pre-existing distribution and licence agreement with
RMW), and excludes the specified territories of China, Macau and Taiwan. The USA and Canada are included for Infectious Disease Indications.
INVIONView entire presentation